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Identification of major cardiovascular
events in patients with diabetes using
primary care data
Koen Bernardus Pouwels1*, Jaco Voorham2, Eelko Hak1 and Petra Denig2
Abstract
Background: Routine primary care data are increasingly being used for evaluation and research purposes but there
are concerns about the completeness and accuracy of diagnoses and events captured in such databases. We
evaluated how well patients with major cardiovascular disease (CVD) can be identified using primary care morbidity
data and drug prescriptions.
Methods: The study was conducted using data from 17,230 diabetes patients of the GIANTT database and Dutch
Hospital Data register. To estimate the accuracy of the different measures, we analyzed the sensitivity, specificity,
positive predictive value (PPV), and negative predictive value (NPV) relative to hospitalizations and/or records with a
diagnosis indicating major CVD, including ischaemic heart diseases and cerebrovascular events.
Results: Using primary care morbidity data, 43 % of major CVD hospitalizations could be identified. Adding drug
prescriptions to the search increased the sensitivity up to 94 %. A proxy of at least one prescription of either a
platelet aggregation inhibitor, vitamin k antagonist or nitrate could identify 85 % of patients with a history of major
CVD recorded in primary care, with an NPV of 97 %. Using the same proxy, 57 % of incident major CVD recorded in
primary or hospital care could be identified, with an NPV of 99 %.
Conclusions: A substantial proportion of major CVD hospitalizations was not recorded in primary care morbidity
data. Drug prescriptions can be used in addition to diagnosis codes to identify more patients with major CVD, and
also to identify patients without a history of major CVD.
Keywords: Cardiovascular diseases, Electronic health records, Diabetes mellitus, Registries, General practice,
Sensitivity and specificity
Background
Routine primary care data are increasingly being used
for evaluation and research purposes. In particular, data
on drug prescriptions, diagnoses and events are used for
(pharmaco)epidemiological and pharmacovigilance stud-
ies and for the evaluation of quality of care. Data are be-
coming more accessible through initiatives, such as
European Network of Centres for Pharmacoepidemiol-
ogy and Pharmacovigilance Resource Database [1]. Val-
idation of information recorded in such databases is
required [2]. This is especially relevant in light of
upcoming electronic patient record systems, such as the
‘care.data’ scheme in the United Kingdom [3], which are
likely to include data from practitioners who are not
submitted to rigorous data quality assurance methods.
There is a growing amount of studies evaluating treat-
ment and cardiovascular outcomes using morbidity data
from primary care databases [4–8], and also disease co-
horts are created using such data [9]. There are con-
cerns, however, about the completeness and accuracy of
the diagnoses and events captured in primary care re-
cords [10, 11]. Recent research from the UK indicates
that a substantial proportion of cardiovascular events is
not adequately recorded in primary care morbidity re-
cords [12]. Previous studies indicated that adding drug
prescriptions may improve the identification of patients
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with ischemic heart disease (IHD) or myocardial infarc-
tion especially when diagnosis recording is poor [13, 14].
Several studies have used drug prescriptions to identify
patients with cardiovascular diseases (Additional file 1:
Appendix A), but there are questions whether and which
drug prescriptions can be used as proxies for identifying
patients with prior cardiovascular diagnoses [15]. Previ-
ous studies were all from the UK and used Read-codes
to identify patients, while the International Classification
of Primary Care (ICPC) codes are more widely used
across Europe. More information about the validity of
morbidity and drug prescription data for identification
of cardiovascular events and of prior cardiovascular dis-
eases (CVD) is needed to assess the potential impact of
misclassification bias in (pharmaco)epidemiological
studies [16, 17]. Given that several studies rely on pri-
mary care records alone or solely on drug prescription
data, there is a need to evaluate how well CVD events
and prior CVD can be identified using these sources of
information.
We first evaluated how well major cardiovascular dis-
ease (CVD) hospitalizations can be identified from pri-
mary care morbidity data and/or drug prescriptions
using a Dutch database with type 2 diabetes patients.
Secondly, we evaluated the accuracy of different drug
proxies to identify patients with a history of major CVD,
and to identify a first major CVD event in patients with-
out a history of CVD (incident major CVD).
Methods
Study population
This study was conducted using data from the
Groningen Initiative to Analyse Type 2 Diabetes Treatment
(GIANTT) database [18]. This database contains anon-
ymized data extracted from electronic medical records of
type 2 diabetes patients managed by general practitioners
in one region in the Netherlands, and includes prescrip-
tions, morbidity, laboratory test results and physical exami-
nations. Morbidity is documented by means of ICPC codes
[19] or short text descriptions, which were manually coded
in GIANTT. In the Netherlands, each patient is registered
with a single GP, who is obliged to keep adequate medical
records regarding all relevant diagnostic and prescription
information, including out-of-hours prescriptions made by
other practitioners. Hence, drug prescriptions were
extracted from the same database as the primary care
morbidity data.
We included those individuals with data on drug pre-
scriptions available between 1 December 2007 and 1 April
2010, based on enrolment data in GIANTT, who were
uniquely linkable with data from the Dutch Hospital Data
(DHD) register provided by Statistics Netherlands and sur-
vived during the study period (1 January 2008 to 31
December 2009) [20]. The linkage was carried out by
Statistics Netherlands, using a match based on gender,
date of birth and the 4-digit part of the postal code. Identi-
fying variables were removed by Statistics Netherlands.
Overall, 88 % of patients were successfully linked.
Included hospitalizations, GP diagnoses and medications
Data on hospitalizations were collected from the DHD
register provided by Statistics Netherlands [20]. Discharge
diagnoses are coded according to the International Classi-
fication of Diseases-9-Clinical Modification (ICD-9) and
procedures are coded according to the Classification of
Medical Procedures developed by the Central Administra-
tion of Procedures in the Netherlands. Major CVD in-
cluded hospitalizations with the following discharge
diagnoses or procedures: IHD (ICD-9 code 410-411,413-
414), cerebrovascular disease (ICD-9 code 430-437), cor-
onary artery bypass grafting (CABG) or percutaneous
transluminal coronary angioplasty (PTCA). Primary care
diagnoses and procedures were collected from the
GIANTT database. Major CVD included IHD (ICPC code
K74-K76), stroke/transient cerebral ischemia (ICPC code
K89-K90), coronary artery bypass grafting or percutaneous
transluminal coronary angioplasty. Drug prescription data
were obtained from the GIANTT database. For the identi-
fication of patients with a major CVD, different cardiovas-
cular drug classes were considered based on previous
studies (Additional file 1: Appendix A).
Identification of hospitalization for major CVD
For our first analysis, all major CVD hospitalizations be-
tween 1 January 2008 and 31 December 2009 were de-
fined as cases. Information about hospitalizations was
obtained from the DHD register. This source has the ad-
vantage of providing the most complete and accurately
dated information on CVD hospitalizations. We evalu-
ated whether these hospitalizations can be identified
using different combinations of primary care morbidity
records and cardiovascular drug prescriptions registered
during the same period. No restrictions were applied re-
garding the maximum time between the hospitalization
and morbidity record or cardiovascular drug prescrip-
tion, as long as both were dated within the 2-year
period.
Identification of history of major CVD
We assessed whether patients with a history of major
CVD, as documented in the primary care morbidity re-
cords (GIANTT data), can be identified using different
cardiovascular drug prescriptions. In the Netherlands,
primary care records provide the most complete disease
history information. Patients with a primary care diagno-
sis for a major IHD or cerebrovascular event before 1
January 2008 were labeled as patients with a history of
major CVD. We evaluated drug prescriptions between 1
Pouwels et al. BMC Health Services Research  (2016) 16:110 Page 2 of 8
January 2008 and 31 December 2008 to estimate the ac-
curacy of different drug proxies. To prevent an under-
estimation of the specificity, we restricted this analysis to
1 year and excluded patients with an event between 1
January 2008 and 31 December 2008.
Identification of incident major CVD
We evaluated whether patients with an incident major
CVD can be identified using different cardiovascular
drug prescriptions. For this, both first major CVD epi-
sodes recorded in primary care (GIANTT data) and first
major CVD hospitalizations (DHD data) were defined as
incident major CVD events. This is expected to provide
the most complete information about the occurrence of
such events, since some events may not lead to a
hospitalization. All first major CVD hospitalizations or
primary care diagnosis between 1 January and 31
December 2009 were defined as incident cases. In case
of multiple events, the earliest date was used as the
index date. This analysis was restricted to 2009, as we
were interested in cardiovascular drug treatment initi-
ation, defined as a first prescription of a cardiovascular
drug with no prescription of that drug in the previous
365 days. Patients who already had at least one pre-
scription of the drug of interest in the year before 1
December 2008 (allowing a 30 day window prior to in-
cident major CVD events, see below) were excluded.
Drug prescriptions prescribed for the first time be-
tween 30 days before and 90 days after the index event
were considered as true positives, when prescribed
more than 30 days before the index event as false posi-
tive, and when prescribed more than 90 days after the
index event as false negatives. The 30 day before and
90 day after thresholds were used to account for pa-
tients receiving their first prescription when scheduled
for a coronary revascularization and patients are not
being prescribed drugs by their general practitioner
during or shortly after hospitalization, respectively.
Statistical analysis
To estimate the accuracy of the different measures, we
analyzed the sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) relative
to hospitalizations and/or records with a diagnosis indi-
cating major IHD or cerebrovascular events. Since the
priority of which accuracy measure to use largely de-
pends on the research question and goal [21], we report
all accuracy measures. Exact binomial 95 % confidence
intervals (95 % CI) were calculated. Data were analyzed
using SPSS 20 Software and R version 3.0.2.
Sensitivity analyses
Various sensitivity analyses were performed. First, we re-
peated analyses for major IHD (ICD-9 410-411, 413-414,
CABG and PTCA vs ICPC K74-K76, CABG and PTCA)
and cerebrovascular disease (ICD-9 430-437 vs ICPC
K89-K90) separately. Second, we evaluated whether the
accuracy measures would improve when comparing
myocardial infarction hospitalizations (ICD-9 code 410),
as a well-defined endpoint, with the primary care codes
for myocardial infarction or chronic ischemic heart dis-
ease, which includes past myocardial infarction (ICPC
codes K75-K76). Similarly, we evaluated accuracy mea-
sures for well-defined cerebrovascular events/stroke
codes (ICD-9 430-434 vs ICPC K90). Third, we tested
the impact of possible registration problems at GP and
DHD level. For this, we excluded 18 GPs with a rela-
tively low morbidity registration, and 63 additional GPs
with a possible delay in registration or situated in an
area for which the closest hospital did not provide
complete data to the DHD register during the entire
study period. Fourth, we explored the influence of using
at least two or three prescriptions within 1 year to iden-
tify patients with a history of major CVD instead of at
least one prescription within a year. Fifth, we compared
the concordance between major CVD hospitalizations
and primary care morbidity records in patients with and
without a history of major CVD. This sensitivity analysis
was performed to assess whether GPs are less likely to
re-enter the diagnostic code in case of a hospitalization
for patients with a history of major CVD.
Ethics statement
In The Netherlands, according to the Code of Conduct
for the use of data in Health Research (“Gedragscode
gezondheidsonderzoek” approved in 2004 by the Dutch
College for Protection of Personal Data, taking into ac-
count Article 25 of the Dutch Act on the Protection of
Personal Data) no ethics committee approval was re-




A cohort of 17,230 patients with type 2 diabetes was eli-
gible for analyses. At baseline, mean age of the study
population was 66 years (sd 12), 48 % were men, median
diabetes duration was 6 years (interquartile range: 3–10)
and the prevalence of at least one major CVD diagnosis
recorded by a GP was 16 %.
Identification of hospitalization for major CVD
Between January 2008 and December 2009, 729 (4 %)
patients were hospitalized for a major CVD event or
procedure. The primary care diagnoses recorded in the
same period had a sensitivity of 43 % and a PPV of 35 %
for identifying major CVD hospitalizations (Table 1).
Adding nitrate prescriptions to the search resulted in a
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sensitivity of 68 % and a PPV of 24 %. A proxy based on
primary care diagnoses, platelet aggregation inhibitor,
vitamin k antagonist or nitrate prescriptions had a sensi-
tivity of 94 % and PPV of 10 %. Major cerebrovascular
hospitalizations were more often identified using pri-
mary care diagnoses alone than major CVD hospitaliza-
tions (57 % vs 38 %). When only considering myocardial
infarction hospitalizations, the sensitivity of primary care
diagnoses was with 46 % still lower than for cerebrovas-
cular hospitalizations (57 %). Restricting the analysis to
only well-defined cerebrovascular events decreased the
sensitivity from 57 to 54 %.
Results were similar for patients with and without a
history of major CVD recorded in primary care morbid-
ity data prior January 2008, e.g. for major CVD hospitali-
zations the sensitivity was 42 % for patients without and
45 % for patients with a history of major CVD.
Identifying history of major CVD
Next, we assessed whether patients with a history of major
CVD (15 % of the included patients) - as documented in
primary care morbidity records - can be identified using
different cardiovascular drug prescriptions. The sensitivity
of 1 prescription of individual drugs ranged between 1 %
for nicotinic acid and derivatives and 70 % for platelet ag-
gregation inhibitors (Table 2 and Additional file 1:
Appendix C). When at least one prescription of either a
platelet aggregation inhibitor, a vitamin k antagonist or
nitrate was used as a proxy, the sensitivity increased to
85 %. When considering only a history of major CVD, this
proxy had a 100 % sensitivity (Table 2). The specificity of
one prescription of individual drugs ranged between
36 % for statins and 100 % for nicotinic acid and deriv-
atives (Additional file 1: Appendix C). The proxy in-
cluding three had a specificity of 75 %. PPVs for
individual drugs ranged between 15 % for thiazides
and 52 % for nitrates (Additional file 1: Appendix C).
The afore mentioned proxy including three drug clas-
ses had a PPV of 37 %. NPVs were equal to or above
85 % for all drug proxies.
Results were similar when using two or more and three
or more prescriptions within 1 year as a requirement for a
positive test (Additional file 1: Appendix D).
Identifying incident major CVD
Using primary care data or hospitalizations indicating in-
cident major CVD as a reference, only 13 % of incident
major CVD events could be identified using nitrate pre-
scriptions alone (Table 3). However, a proxy based on
one prescription of either a platelet aggregation inhibi-
tor, a vitamin k antagonist or nitrate identified 57 % of
incident major CVD events. This proxy had a specificity
of 94 % and a PPV of 17 %.
When using only hospitalizations as a reference, the
sensitivity of this proxy increased to 71 %, while the spe-
cificity and PPV were 94 and 12 %, respectively.
Table 1 Identifying major IHD or cerebrovascular hospitalizations









GP codes 312 567 15934 417 43 (39–46) 97 (96–97) 35 (32–39) 97 (97–98)
GP codes/nitrates 498 1602 14899 231 68 (65–72) 90 (90–91) 24 (22–26) 98 (98–99)
GP codes/nitrates/platelet aggregation inhibitors 672 5123 11378 57 92 (90–94) 69 (68–70) 12 (11–12) 100 (99–100)
GP codes/nitrates/platelet aggregation inhibitors/vitamin
k antagonists
685 6297 10204 44 94 (92–96) 62 (61–63) 10 (9–11) 100 (99–100)
IHD hospitalizations
GP codes 212 431 16240 347 38 (34–42) 97 (97–98) 33 (29–37) 98 (98–98)
GP codes/nitrates 391 1499 15172 168 70 (66–74) 91 (91–91) 21 (19–23) 99 (99–99)
GP codes/nitrates/platelet aggregation inhibitors 520 5217 11454 39 93 (91–95) 69 (68–69) 9 (8–10) 100 (100–100)
GP codes/nitrates/platelet aggregation inhibitors/vitamin
k antagonists
529 6421 10250 30 95 (92–96) 61 (61–62) 8 (7–8) 100 (100–100)
Cerebrovascular hospitalizations
GP codes 105 172 16874 79 57 (50–64) 99 (99–99) 38 (32–44) 100 (99–100)
GP codes/platelet aggregation inhibitors 161 5162 11884 23 88 (82–92) 70 (69–70) 3 (3–4) 100 (100–100)
GP codes/platelet aggregation inhibitors/vitamin k antagonists 168 6603 10443 16 91 (86–95) 61 (61–62) 2 (2–3) 100 (100–100)
Abbreviations: IHD ischaemic heart disease, GP general practitioner, TP true positive, FP false positive, TN true negative, FN false negative, Sens sensitivity, Spec
specificity, PPV positive predictive value, NPV negative predictive value
aGP codes are the following primary care diagnoses: angina pectoris (ICPC code K74), myocardial infarction (ICPC code K75), other or chronic ischemic heart
disease (ICPC code K76), transient cerebral ischemia (ICPC code K89), stroke or cerebrovascular accident (ICPC code K90), coronary artery bypass grafting or
percutaneous transluminal coronary angioplasty
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Table 2 Identifying a history of major IHD or cerebrovascular disease using GP diagnoses as a reference standard









Vitamin K antagonists 424 1029 12996 2010 17 (16–19) 93 (92–93) 29 (27–32) 87 (86–87)
Platelet aggregation inhibitors 1696 2500 11525 738 70 (68–72) 82 (82–83) 40 (39–42) 94 (94–94)
Nitrates 487 441 13584 1947 20 (18–22) 97 (97–97) 52 (49–56) 87 (87–88)
Vitamin K antagonists/Platelet aggregation inhibitors 2045 3441 10584 389 84 (83–85) 75 (75–76) 37 (36–39) 96 (96–97)
Vitamin K antagonists/Platelet aggregation inhibitors/Nitrates 2077 3519 10506 357 85 (84–87) 75 (75–76) 37 (36–38) 97 (96–97)
IHD history
Vitamin K antagonists 354 1099 13453 1553 19 (17–20) 92 (92–93) 24 (22–27) 90 (89–90)
Platelet aggregation inhibitors 1312 2884 11668 595 69 (67–71) 80 (80–81) 31 (30–33) 95 (95–96)
Nitrates 466 462 14090 1441 24 (23–26) 97 (97–97) 50 (47–53) 91 (90–91)
Vitamin K antagonists/Platelet aggregation inhibitors 1603 3883 10669 304 84 (82–86) 73 (73–74) 29 (28–30) 97 (97–98)
Vitamin K antagonists/Platelet aggregation inhibitors/Nitrates 1907 3961 10591 0 100 (100–100) 73 (72–74) 32 (31–34) 100 (100–100)
Cerebrovascular history
Vitamin K antagonists 119 1334 14424 582 17 (14–20) 92 (91–92) 8 (7–10) 96 (96–96)
Platelet aggregation inhibitors 506 3690 12068 195 72 (69–75) 77 (76–77) 12 (11–13) 98 (98–99)
Nitrates 67 861 14897 634 10 (7–12) 95 (94–95) 7 (6–9) 96 (96–96)
Vitamin K antagonists/Platelet aggregation inhibitors 604 4882 10876 97 86 (83–89) 69 (68–70) 11 (10–12) 99 (99–99)
Vitamin K antagonists/Platelet aggregation inhibitors/Nitrates 604 4992 10766 97 86 (83–89) 68 (68–69) 11 (10–12) 99 (99–99)
Abbreviations: IHD ischaemic heart disease, GP general practitioner, TP true positive, FP false positive, TN true negative, FN false negative, Sens sensitivity, Spec
specificity, PPV positive predictive value, NPV negative predictive value
Table 3 Identifying incident major IHD or cerebrovascular eventsa









Vitamin K antagonists 16 324 14689 569 3 (2–4) 98 (98–98) 5 (3–8) 96 (96–97)
Platelet aggregation inhibitors 147 495 11654 167 47 (41–53) 96 (96–96) 23 (20–26) 99 (98–99)
Nitrates 73 308 15196 470 13 (11–17) 98 (98–98) 19 (15–23) 97 (97–97)
Vitamin K antagonists/Platelet aggregation inhibitors 129 626 10230 106 55 (48–61) 94 (94–95) 17 (14–20) 99 (99–99)
Vitamin K antagonists/Platelet aggregation inhibitors/Nitrates 132 650 10088 98 57 (51–64) 94 (93–94) 17 (14–20) 99 (99–99)
Hosp IHD/cerebrovascular eventsc
Vitamin K antagonists 13 331 14944 310 4 (2–7) 98 (98–98) 4 (2–6) 98 (98–98)
Platelet aggregation inhibitors 107 545 11744 68 61 (53–68) 96 (95–96) 16 (14–19) 99 (99–100)
Nitrates 59 330 15431 227 21 (16–26) 98 (98–98) 15 (12–19) 99 (98–99)
Vitamin K antagonists/Platelet aggregation inhibitors 92 673 10282 44 68 (59–75) 94 (93–94) 12 (10–15) 100 (99–100)
Vitamin K antagonists/Platelet aggregation inhibitors/Nitrates 94 697 10137 39 71 (62–78) 94 (93–94) 12 (10–14) 100 (99–100)
Abbreviations: IHD ischaemic heart disease, GP general practitioner, Hosp hospitalization, TP true positive, FP false positive, TN true negative, FN false negative, Sens
sensitivity, Spec specificity, PPV positive predictive value, NPV negative predictive value
aPrescriptions are considered to be in agreement with actual events if being prescribed between 30 days before to 90 days after the date of the major IHD or
cerebrovascular event
bUsing hospitalizations or general practitioners diagnoses as reference standard
cUsing only hospitalizations as reference standard
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Removing patients from GPs with possible registration
problems did not alter the findings substantially
(Additional file 1: Appendices B, E and F).
Discussion
Only 43 % of major CVD hospitalizations could be iden-
tified using diagnoses recorded in primary care in the
same period. Adding drug prescriptions to the search in-
creased the sensitivity up to 94 %. The proxy of at least
one prescription of either a platelet aggregation inhibi-
tor, a vitamin k antagonist or nitrate prescription could
identify 85 % of patients with a history of major CVD re-
corded in primary care. With this drug prescription
proxy, also 57 % of the incident major CVD recorded in
either primary or hospital care records could be
identified.
Our finding that less than half of the hospitalizations
for a major CVD were identified using primary care
morbidity records indicates that even for major events
such records are incomplete. Focusing only on myocar-
dial infarction slightly increased this figure to 46 %. For
comparison, it was estimated that approximately 25 % of
myocardial infarctions were not recorded in primary
care morbidity records of the widely researched Clinical
Practice Research Datalink (CPRD) [12]. For some of the
included morbidity codes, it is possible that general
practitioners do not immediately enter a new diagnosis
in their system after receiving a discharge letter from the
hospital. The CPRD study found that in primary care re-
cords the discharge date is often used to record myocar-
dial infarctions [12], which may especially for
hospitalizations with a long duration result in misclassi-
fication of the date of the event. In addition, some pa-
tients may already have a history of major CVD which
theoretically may reduce the likelihood to re-enter the
diagnostic code in case of a hospitalization. However,
our results were similar for patients with and without a
history of major CVD recorded in primary care morbid-
ity data. Therefore, adding drug proxies to morbidity
codes may be useful to identify patients with major CVD
when the quality of diagnosis coding is poor [14].
The selected drugs had a relatively high specificity to
identify both a history of major CVD and incident CVD,
although some of the evaluated drugs may be prescribed
for other indications. For example, a Dutch study found
that 41 % of 8,718 patients receiving antiplatelet therapy
had only a non-recommended cardiovascular indication
(n = 982) or related cardiometabolic disease (n = 2,557)
recorded, suggesting frequent use of these drugs for
primary prevention [22]. In addition, some of the eval-
uated drugs are used for other indications, such as
venous thrombosis. Previous research suggested that
nitrate prescriptions can be used to identify patients
with CVD [13, 14, 23]. Our study confirms that
nitrates indeed have the highest specificity to identify
such patients but the sensitivity is lower than found in
the other studies (24 % vs 47–55 %) [13, 14]. This dif-
ference may be due to the fact that we used a broader
reference standard, that is, all patients with acute an-
gina pectoris, myocardial infarction, chronic ischemic
heart disease, CABG or PTCA recorded in primary
care morbidity data. Donnan et al. evaluated whether
patients with a myocardial infarction could be identi-
fied using nitrate prescriptions [14], while Gray et al.
evaluated whether nitrates could be used to identify
patients with ischemic heart disease, including prob-
able cases defined as patients with a written record
strongly suggesting ischemic heart disease and receiv-
ing drugs that could be used to treat angina [13]. As
nitrates, which are frequently used to treat angina,
were consequently used to create the golden standard
in that study, one would expect a higher sensitivity
than in our study.
Both for identifying a history of CVD and incident
major CVD events, a combined drug proxy including
also vitamin K antagonists and platelet aggregation in-
hibitors had a much higher sensitivity than nitrates
alone, with some loss in specificity. As already pointed
out earlier by McManus et al., strokes may be difficult to
identify using drug prescriptions [24]. Approximately
10 % of strokes are due to hemorrhagic strokes [25, 26],
which are particularly difficult to identify using drug
prescriptions. This may explain why a history of major
CVD events could be better identified using drug pre-
scriptions than a history of major cerebrovascular
events, despite the fact that major cerebrovascular hos-
pitalizations were better registered in primary care mor-
bidity records.
In general, the PPVs for identification of patients with
major CVD were low. This is partly because the majority
of patients did not have a major CVD diagnosis and may
have other indications for which the selected drugs can
be prescribed, such as venous thrombosis [22]. To iden-
tify as many patients with major CVD as possible from
primary care records one needs a search strategy with a
high sensitivity, thus using both diagnosis codes and
drug proxies. On the other hand, for selecting a cohort
of primary prevention patients, a high NPV is important.
Our study illustrates that using drug proxies only can be
adequate with a NPV of 97 %, in a population with a
similar prevalence of major CVD.
This study has some important strengths. This is the
first study that evaluates the accuracy of a wide range of
primary care diagnoses and drug prescriptions for identi-
fication of patients with major CVD. We evaluated the
accuracy of general practice morbidity records using
ICPC codes supplemented with diagnoses obtained from
verbal descriptions, thereby capturing more major CVD
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events in general practice morbidity records then when
solely relying on diagnostic codes. Moreover, ICPC codes
are more widely used across Europe than the Read codes
that were used in most previous validation studies. In
addition, we evaluated whether incident and a history of
any major CVD could be identified, while most previous
studies evaluated only specific cardiovascular outcomes,
such as myocardial infarction [14], angina [27] or ath-
erothrombosis [22].
This study has also some limitations. Underlying most
studies assessing the validity of search algorithms to
identify patients with a specific disease is the lack of a
true golden standard registry. This limitation is particu-
larly relevant when evaluating the validity of drug prox-
ies for the identification of patients with CVD in
primary care records. As we found that only 43 % of
major CVD hospitalizations were recorded in primary
care morbidity data, it can be expected that the specifi-
city of the different drug proxies are underestimates of
the true values. Furthermore, some events identified
using primary care morbidity data may be minor events
not requiring hospitalization or working hypotheses.
Despite the lack of a golden standard, we preferred pre-
senting accuracy measures like sensitivity, specificity,
positive predictive value and negative predictive value
over a single agreement measure like kappa, because
these accuracy measures provide better insight about,
for example, what percentage of hospitalizations is not
in primary care morbidity records. We presented data
for patients managed in primary care in the Northern
Netherlands, which may limit the generalizability of our
findings. Individual practices, practices from other re-
gions or countries may register morbidity worse or bet-
ter and may differ in their prescribing habits. Also,
prescribing habits may differ for specific subpopulations.
On the other hand, our analyses based on GIANTT data
represent 80 % of all general practices in the region.
Therefore, the data provide a ‘real-world’ picture of GPs
using electronic health-care records in the community.
In contrast, practices included in special registration net-
works with rigorous data quality assurance methods may
have better morbidity registration.
We only included patient surviving the whole study
period and hence could not assess fatal events or con-
cordance in patients that died within the study period.
Hence, results should not be generalized for studying
fatal CVD events. On the other hand, fatal major CVD
events are less relevant when selecting a cohort of pa-
tients with or without a history of major CVD or identi-
fying more patients than with diagnosis codes alone, i.e.
the situations where drug proxies are often used.
Finally, we had to exclude 12 % of patients who were
not uniquely identifiable in the Dutch Hospital Data
register for the whole study period. Not all hospitals
provide complete data to the DHD register during the
entire study period. However, removing patients from
practices in the area for which the closest hospital did
not provide complete data to DHD did not substantially
influence the results.
In future projects, the accuracy and completeness of
diagnoses in electronic medical records may be im-
proved by investigating free text parts using text-mining
techniques [28–30]. Furthermore, there are also initia-
tives to improve recording of diagnoses in electronic
medical records [31, 32]. The finding that a large pro-
portion of major CVD hospitalizations is not recorded
in primary care morbidity data is particularly relevant in
the context of upcoming regional and nationwide elec-
tronic healthcare databases.
Conclusions
In conclusion, a substantial proportion of major CVD hos-
pitalizations was not recorded in primary care morbidity
data. This stresses the importance of combining different
types of data and linkage of different data sources to iden-
tify patients with incident or prevalent diseases. Using drug
prescriptions as proxies may help to increase the identifica-
tion of patients with major CVD. Moreover, although it ap-
peared difficult to identify patients with incident major
CVD using only drug prescriptions, it seems feasible to se-
lect a cohort of patients without a history of major CVD
using a proxy of at least 1 prescription of either a platelet
aggregation inhibitor, a vitamin k antagonist or nitrate.
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